Basilea Pharmaceutica Ltd. (SWX:BSLN) announces that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in several EU member states and in Switzerland.
(Source: www.pharmalive.com)
No comments:
Post a Comment